This interview will focus on the current treatment landscape and the prescribing patterns of Lexicon's dual SGLT1 and SGLT2 inhibitor Inpefa (sotagliflozin) in patients with heart failure
This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second Look: Discussing the standard of care and potential of Inpefa (sotagliflozin), for treating patients with heart failure with current prescribers of the medication
Ticker(s): LXRXWho's the expert?
Institution: Cleveland Clinic
- Cardiothoracic surgeon and Director ofPerioperative care at Cleveland Clinic.
- Currently manages 20 patients per month with heart failure and has recently started prescribing Inpefa at his practice and has prescribed Inpefa to his 1st patient last month.
- Has been involved in more than 300 peer review publications and serves on the editorial board in numerous cardiovascular and thoracic surgery related journals.
Interview Goal
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
